NeurAxis (NASDAQ:NRXS – Get Free Report) and Medtronic (NYSE:MDT – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Medtronic acquired Stimgenics in January 2020 to expand its portfolio in Differential Target Multiplexed Spinal Cord ...

Deep Brain Stimulator MarketThe global deep brain stimulator market, valued at USD 1308.0 Million in 2024, is projected to grow steadily, reaching USD  2772.1 billion by 2034. With an anticipated CAGR ...

Inceptiv is a small device, implanted in the lower torso with leads to the spinal cord, that provides responsive counter-stimulation to relieve chronic pain. The device was approved by the FDA in ...

using spinal cord transcutaneous stimulation (scTS). This promising approach to enhance cardiovascular regulation addresses the challenges of unstable blood pressure and the accompanying ...

Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot ...

Spinal cord and dorsal root ganglion stimulation are established ... patients received devices from Boston Scientific, 27.5% from Medtronic, 22.5% from Nevro, 11.8% from Abbott, and 1.3% from ...

Medtronic said approval came on the back of results from the pivotal SPHERE Per-AF study, an FDA IDE trial. It compared Sphere-9 with Affera to the J&J Thermocool SmartTouch SF RF ablation ...

24, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Affera™ Mapping and ...